UY31710A - Anticuerpos monoclonales y su método de obtención - Google Patents

Anticuerpos monoclonales y su método de obtención

Info

Publication number
UY31710A
UY31710A UY0001031710A UY31710A UY31710A UY 31710 A UY31710 A UY 31710A UY 0001031710 A UY0001031710 A UY 0001031710A UY 31710 A UY31710 A UY 31710A UY 31710 A UY31710 A UY 31710A
Authority
UY
Uruguay
Prior art keywords
cells
antibody
disclosed
obtaining
monoclonal antibodies
Prior art date
Application number
UY0001031710A
Other languages
English (en)
Inventor
Lombardero Valladares Josefa
Rolando Perez Rodriguez
Jose Enrique Montero Casimiro
Melarkode Ramakrishnan
Nair Pradip
Sundarajaj David Rajkumar
Kedarnath Nanjund Sastry
Chatterji Monalisa
Adhikary Laxmi
Balasubramanian Hema
Original Assignee
Centro Inmunologia Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular, Biocon Ltd filed Critical Centro Inmunologia Molecular
Publication of UY31710A publication Critical patent/UY31710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan un anticuerpo humanizado anti-CD6 de isotipo IgG1 (T1h) que se une al dominio 1(D1) del CD6 que es un receptor tipo SRCR (Scavenger Receptor CysteineRich) presente en la superficie de células del timo , monocitos, células T activadas y una variedad de otros tipos de células. Se divulgan los métodos para inhibir la proliferación de células T sin bloquear la interacción del CD6 y los ligandos naturales del CD6, como al ALCAM (del inglés: Activated Leukocyte Cell Adhesión MOLECULE), y el método de tratamiento de varias enfermedades utilizando el anticuerpo anti-CD6 que reconoce el D1 TIPO SCCR del CD6.
UY0001031710A 2008-03-14 2009-03-13 Anticuerpos monoclonales y su método de obtención UY31710A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14

Publications (1)

Publication Number Publication Date
UY31710A true UY31710A (es) 2009-11-10

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031710A UY31710A (es) 2008-03-14 2009-03-13 Anticuerpos monoclonales y su método de obtención

Country Status (26)

Country Link
US (6) US8524233B2 (es)
EP (2) EP2993186B1 (es)
JP (3) JP2011513479A (es)
KR (1) KR20100126811A (es)
CN (1) CN101970493A (es)
AR (1) AR072247A1 (es)
AU (1) AU2008352540B2 (es)
BR (1) BRPI0822447A2 (es)
CA (1) CA2716919C (es)
CL (1) CL2009000618A1 (es)
CO (1) CO6331445A2 (es)
DK (1) DK2993186T3 (es)
EA (1) EA201001467A1 (es)
ES (1) ES2759075T3 (es)
HK (1) HK1223941A1 (es)
IL (1) IL207917A0 (es)
MX (1) MX2010010085A (es)
MY (1) MY159517A (es)
NZ (1) NZ587632A (es)
PL (1) PL2993186T3 (es)
PT (1) PT2993186T (es)
TW (1) TWI485160B (es)
UA (1) UA104587C2 (es)
UY (1) UY31710A (es)
WO (1) WO2009113083A1 (es)
ZA (1) ZA201005843B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2119453T3 (pl) * 2006-12-26 2015-10-30 Centro De Inmunolgia Molecular Kompozycje farmaceutyczne zdolne do indukcji apoptozy w komórkach guza, przydatne do diagnozowania i leczenia B-komórkowej przewlekłej białaczki limfocytowej
CA2716919C (en) 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2016001042A (es) * 2013-07-23 2017-01-05 Biocon Ltd Metodos para controlar los niveles de fucosilacion en proteinas.
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
WO2016130901A2 (en) * 2015-02-12 2016-08-18 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
WO2017218750A1 (en) * 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce CD6 phosphorylation
EP3529274B1 (en) * 2016-10-21 2024-04-17 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
WO2019169015A1 (en) 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
JP7376564B2 (ja) * 2018-06-29 2023-11-08 シティ・オブ・ホープ 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
CN117980337A (zh) 2021-09-08 2024-05-03 分子免疫中心 抗cd6单克隆抗体在预防由高炎症反应引起的细胞和器官损伤中的用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
WO1995012614A1 (en) 1993-11-02 1995-05-11 Duke University Cd6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN100360184C (zh) 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
SK282894B6 (sk) 1996-03-20 2003-01-09 Hoechst Marion Roussel Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
AU7467898A (en) * 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
AU2001250814B2 (en) 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
CA2555820C (en) * 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
SG155883A1 (en) 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
MX2007009091A (es) 2005-01-28 2008-01-11 Wyeth Corp Formulaciones de polipeptido liquidas estabilizadas.
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
MX2009006199A (es) 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
DK2119452T3 (da) * 2006-12-26 2020-04-20 Ct Inmunologia Molecular Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis
PL2119453T3 (pl) 2006-12-26 2015-10-30 Centro De Inmunolgia Molecular Kompozycje farmaceutyczne zdolne do indukcji apoptozy w komórkach guza, przydatne do diagnozowania i leczenia B-komórkowej przewlekłej białaczki limfocytowej
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
CA2716919C (en) * 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
MX2012005863A (es) 2009-11-20 2013-01-18 Centro Inmunologia Molecular Formulaciones de anticuerpos.
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
MX2016001042A (es) 2013-07-23 2017-01-05 Biocon Ltd Metodos para controlar los niveles de fucosilacion en proteinas.
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
WO2017218750A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
WO2018024896A1 (en) 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) EX VIVO GENERATION OF γδ FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF
IL266087B2 (en) 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce CD6 phosphorylation
EP3529274B1 (en) 2016-10-21 2024-04-17 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
WO2019169015A1 (en) 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CN116963746A (zh) 2020-12-04 2023-10-27 伊奎利厄姆股份有限公司 选择性靶向cd6高细胞并降低teff细胞的活性的方法

Also Published As

Publication number Publication date
MY159517A (en) 2017-01-13
CA2716919C (en) 2015-01-20
NZ587632A (en) 2012-06-29
US10000573B2 (en) 2018-06-19
US20160168256A1 (en) 2016-06-16
ES2759075T3 (es) 2020-05-07
PT2993186T (pt) 2019-11-29
US8524233B2 (en) 2013-09-03
US10669346B2 (en) 2020-06-02
UA104587C2 (ru) 2014-02-25
JP2011513479A (ja) 2011-04-28
JP5856209B2 (ja) 2016-02-09
AR072247A1 (es) 2010-08-18
TW201000125A (en) 2010-01-01
EP2993186A1 (en) 2016-03-09
CA2716919A1 (en) 2009-09-17
US20180258179A1 (en) 2018-09-13
EP2993186B1 (en) 2019-09-04
EA201001467A1 (ru) 2011-06-30
US20170281808A1 (en) 2017-10-05
EP2265644A4 (en) 2011-04-27
HK1223941A1 (zh) 2017-08-11
BRPI0822447A2 (pt) 2015-06-16
AU2008352540B2 (en) 2012-06-28
PL2993186T3 (pl) 2020-02-28
JP2014065711A (ja) 2014-04-17
US9670285B2 (en) 2017-06-06
CO6331445A2 (es) 2011-10-20
US20140031529A1 (en) 2014-01-30
EP2265644A1 (en) 2010-12-29
US20210122829A1 (en) 2021-04-29
US9217037B2 (en) 2015-12-22
TWI485160B (zh) 2015-05-21
ZA201005843B (en) 2011-04-28
CN101970493A (zh) 2011-02-09
KR20100126811A (ko) 2010-12-02
WO2009113083A1 (en) 2009-09-17
JP2014159425A (ja) 2014-09-04
US20110002939A1 (en) 2011-01-06
US11981743B2 (en) 2024-05-14
IL207917A0 (en) 2010-12-30
AU2008352540A1 (en) 2009-09-17
MX2010010085A (es) 2011-03-29
CL2009000618A1 (es) 2011-05-27
DK2993186T3 (da) 2019-11-25

Similar Documents

Publication Publication Date Title
UY31710A (es) Anticuerpos monoclonales y su método de obtención
UY31707A1 (es) Composiciones herbicidas que comprenden piroxasulfona vii
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
AR107902A2 (es) Anticuerpos anti-cd37
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CO6260105A2 (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20091404A1 (es) Composiciones y metodos para el tratamiento de tumores de origen hematopoyetico
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
RU2013113933A (ru) Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl
CO6351749A2 (es) Anticuerpos de interleucina-1 alfa y metodos de uso
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
EA201071137A1 (ru) Способы лечения
AR065496A1 (es) Anticuerpos anti- il-23 r
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
AR072167A1 (es) Anticuerpos contra il-6 humano y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EA201790757A1 (ru) Связывающие антиген cd27l белки
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017